Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Promethera raises €39.7mm through Series D round; closes round at €47.2mm

Executive Summary

Promethera Biosciences SA NV raised €39.7mm ($44.4mm) through its Series D round. Itochu Corp. co-led the round with a €10mm investment, along with Shinsei Capital Partners, and the pair were joined by additional buyers Medipal Holdings, Mirae Asset Capital, the family office Six Snow, Korea Investment Partners, Ci:z Investment LLP, Mitsui & Co., and Belgian private investors. Proceeds will support Promethera's HepaStem cell technology platform (liver-derived stem cells from healthy donated organs and expanded in a lab) for acute-on-chronic liver failure (ACLF) and initiation of a clinical trial in NASH.

Update 12/16/2019

Promethera announced that it received a final closing of €7.5mm ($8.36mm), bringing the Series D total of €47.2mm. New investors Sony Innovation Fund by IGV and Pegasus Tech Ventures led the tranche. New proceeds will be used to advance NASH and acute-on-chronic liver failure candidates, and accelerate the company's growth in Asian markets.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies